Nykredit A S Acquires New Position in Becton, Dickinson and Company $BDX

Nykredit A S acquired a new stake in Becton, Dickinson and Company (NYSE:BDX) during the second quarter, Holdings Channel.com reports. The institutional investor acquired 102,662 shares of the medical instruments supplier’s stock, valued at approximately $15,536,000.

Other large investors have also modified their holdings of the company. Imprint Wealth LLC acquired a new position in Becton, Dickinson and Company during the third quarter worth $25,000. SHP Wealth Management acquired a new stake in Becton, Dickinson and Company in the fourth quarter valued at $26,000. Meeder Asset Management Inc. boosted its position in shares of Becton, Dickinson and Company by 152.2% during the 1st quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock worth $27,000 after purchasing an additional 102 shares in the last quarter. Prosperity Bancshares Inc purchased a new stake in shares of Becton, Dickinson and Company during the 4th quarter worth $29,000. Finally, Main Street Group LTD acquired a new position in shares of Becton, Dickinson and Company during the 1st quarter worth $29,000. 86.97% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

BDX has been the subject of several recent analyst reports. Wells Fargo & Company raised their price objective on shares of Becton, Dickinson and Company from $161.00 to $170.00 and gave the company an “equal weight” rating in a research note on Friday, August 7th. Royal Bank Of Canada upped their target price on shares of Becton, Dickinson and Company from $180.00 to $190.00 and gave the stock a “sector perform” rating in a research report on Thursday, August 13th. Citigroup reiterated a “buy” rating on shares of Becton, Dickinson and Company in a research report on Thursday, August 13th. TD Cowen boosted their price target on Becton, Dickinson and Company from $163.00 to $182.00 and gave the stock a “hold” rating in a research note on Wednesday, August 5th. Finally, Barclays upped their price target on Becton, Dickinson and Company from $202.00 to $204.00 and gave the stock an “overweight” rating in a report on Monday, May 11th. Eight research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $187.67.

Becton, Dickinson and Company Price Performance

Shares of NYSE BDX opened at $184.78 on Friday. The company has a current ratio of 0.87, a quick ratio of 0.51 and a debt-to-equity ratio of 0.55. The company’s 50-day moving average price is $170.05 and its 200 day moving average price is $160.69. Becton, Dickinson and Company has a 52 week low of $127.59 and a 52 week high of $193.07. The stock has a market cap of $50.91 billion, a price-to-earnings ratio of 55.66, a PEG ratio of 13.22 and a beta of 0.21.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.14 by $0.09. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The company had revenue of $4.98 billion during the quarter, compared to analysts’ expectations of $4.89 billion. During the same quarter in the previous year, the business posted $3.68 earnings per share. The firm’s quarterly revenue was up 5.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, research analysts forecast that Becton, Dickinson and Company will post 12.67 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th will be given a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a dividend yield of 2.3%. The ex-dividend date is Wednesday, September 9th. Becton, Dickinson and Company’s payout ratio is currently 126.51%.

Insider Buying and Selling

In other Becton, Dickinson and Company news, EVP Michael Feld sold 165 shares of the stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $188.49, for a total transaction of $31,100.85. Following the sale, the executive vice president owned 19,720 shares in the company, valued at approximately $3,717,022.80. This represents a 0.83% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas Polen, Jr. sold 4,152 shares of the firm’s stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $185.00, for a total value of $768,120.00. Following the transaction, the chief executive officer directly owned 110,163 shares of the company’s stock, valued at $20,380,155. The trade was a 3.63% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 9,105 shares of company stock worth $1,590,208 in the last quarter. Corporate insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.